What's Happening?
Mapi Pharma Ltd., a late-stage clinical biopharmaceutical company based in Israel, has announced plans to explore the establishment of a U.S.-based aseptic manufacturing facility. This initiative aims
to support the company's expanding pipeline and the increasing global demand for aseptic and long-acting injectable therapies. Mapi Pharma will present this plan at the SelectUSA Investment Summit in National Harbor, Maryland, where it will engage with potential partners and investors. The company specializes in long-acting injectable therapies, which are gaining recognition for their benefits in patient adherence and consistent drug delivery. Mapi Pharma has already developed advanced R&D and GMP-compliant manufacturing capabilities in Israel, approved by the Israeli Ministry of Health and recognized by European regulatory authorities.
Why It's Important?
The establishment of a U.S. manufacturing facility by Mapi Pharma is significant as it positions the company to better serve the largest market for aseptic and long-acting injectables, including therapies for central nervous system disorders and metabolic diseases. This move could enhance the company's ability to commercialize its products and ensure a reliable supply chain for patients worldwide. The U.S. facility would also allow Mapi Pharma to leverage its expertise in developing complex injectable therapies, potentially leading to new partnerships and investment opportunities. The company's focus on long-acting formulations, such as Cariprazine Depot, addresses unmet needs in conditions like schizophrenia and bipolar disorder, highlighting the potential impact on public health.
What's Next?
Mapi Pharma is exploring a partnership-based structure for the U.S. manufacturing project, which may involve forming a new entity with strategic and financial investors. The company plans to use its existing expertise and investments while seeking partners for capital investment and commercial capabilities. The SelectUSA Investment Summit will provide a platform for Mapi Pharma to discuss strategic partnerships and joint development opportunities. The company is also preparing for the Phase III initiation of its long-acting Cariprazine Depot program in 2027, which could further solidify its position in the market for long-acting injectable therapies.
